Application of Antiosteoporosis Therapy in Osteolysis

Complication Clinical Trial

Official title:

Efficacy and Safety of Antiosteoporosis Therapy in Patients After Bone Tumor Resection: a Multicenter, Real-world Prospective Cohort Observational Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05617846
• Other study ID #: ZZUSC-19
• Status: Not yet recruiting
• Start date: December 28, 2024
• Est. completion date: November 30, 2032

Study information

• Verified date: August 2023
• Source: Henan Cancer Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To report the postoperative complications and limb function of patients with osteolysis after surgery for bone tumors of the extremities who received anti-osteoporosis therapy in Henan Cancer Hospital in the next 10 years.

Description:

A total of 100 patients with osteolysis after surgery for bone tumors of the four extremities who received anti-osteoporosis treatment in Henan Cancer Hospital in the next 10 years were reported. The basic information, treatment methods, postoperative complications and limb function of these patients were collected.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: November 30, 2032
• Est. primary completion date: November 30, 2032
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. No age restriction, male or female.

2. A subtype of bone tumor (including benign, malignant, and metastatic cancer) was confirmed in the pathology department of the research institution.

3. Received excision of bone tumor in research institution.

Exclusion Criteria:

Not applicable.

Related Conditions & MeSH terms

• Complication

Intervention

Other:
• Anti-osteoporosis therapy
Bone healing, limb function, and complications of postoperative osteolysis in patients with bone tumors of the extremities treated with anti-osteoporosis therapy.

Locations

Country	Name	City	State
China	Department of Bone and Soft Tissue ,Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Henan Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complications	The incidence of complications after anti-osteoporosis treatment was collected and the severity of complications was evaluated according to CTCAE5.0.	Collected from the beginning of treatment to 24 months after treatment.
Primary	Limb function	Limb function was assessed using the Musculoskeletal Oncology Society (MSTS) scoring scale for seven items, namely movement, pain, stability, deformity, strength, functional activity, and emotional receptiveness. The highest possible score is 35, with 5 points allocated to each project.	Collected from the beginning of treatment to 24 months after treatment.